



# WARREN HOSPITAL

185 Roseberry Street • Phillipsburg, New Jersey 08865  
Telephone (908) 859-6700

NMSS

License No. 29-01101-03

03002431

April 27, 2007

USNRC Region 1  
475 Allendale Road  
King of Prussia PA 19406-1415

Gentlemen:

Please make the following changes to our radioactive materials license:

- |                              |   |
|------------------------------|---|
| Remove as Authorized User(s) | Stuart Miller, M.D.   |
| Add as Authorized User(s)    | Stephen Ksiazek, M.D., 35.100, 35.200<br>(ref. 37-09938-01) |
|                              | Joel D. Neuman, M.D., 35.100, 35.200<br>(ref. 37-09938-01)  |
|                              | Devendra K. Amin, M.D., 35.100, 35.200<br>(see attachments) |

For questions regarding these changes you may call John C. Ramsey at 908-788-9440.

Thank you.

Sincerely yours,  
WARREN HOSPITAL

  
Jeffrey Goodwin  
Chief Executive Officer

140466

REC'D IN LAT MAY - 1 2007

**CEDARS-SINAI MEDICAL CENTER**

May 30, 2006

Rebecca Bock  
Chairman, Radiation Safety Committee  
Warren Hospital  
185 Rosberry Street  
Phillipsburg, NJ 08865

RE: Devendra K. Amin, MD Nuclear Medicine Accreditation

Dear Ms. Bock:

Devendra K. Amin, MD successfully completed the Cardiology Clinical and Research Fellowship at Cedars-Sinai Medical Center (1982-1984) under my direction. Cardiology Fellows during this period received Level 2 training. The American College of Radiology defines Level 2 training as:

1. a minimum of 700 hours of didactic, clinical study interpretation and hands-on clinical case and radiation safety training in nuclear cardiology,
2. a minimum of 300 cases interpreted

Sincerely,

Daniel S. Berman, MD  
Professor of Medicine, David Geffen School of Medicine at UCLA  
Director, Cardiac Imaging, Cedars-Sinai Medical Center

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 3 PAGES  
Amendment No. 48

Duplicate

MATERIAL Duplicate

Duplicate

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

|   |   |
|---|---|
| <p>Licensee</p> <p>1. Northampton Hospital Corporation<br/>c/b/a Easton Hospital</p> <p>2. 21st and Lehigh Streets<br/>Easton, Pennsylvania 18042</p> | <p>In accordance with this letter dated November 22, 2002,</p> <p>3. License number 37-09938-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date June 30, 2011</p> <p>5. Docket No. 030-09119<br/>Reference No. SOB9938</p> |
|---|---|

|   |   |  |
|---|---|--|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p> <p>D. Any byproduct material permitted by 10 CFR 35.400</p> <p>E. Any byproduct material permitted by 10 CFR 31.11</p> <p>F. Uranium depleted in Uranium 235</p> | <p>Chemical and/or physical form</p> <p>A. Any</p> <p>C. Any</p> <p>D. Sealed sources</p> <p>E. Prepackaged Kits</p> <p>F. Cadmium plated metal</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> <p>1000 millicuries</p> <p>D. 2000 millicuries</p> <p>E. 5 millicuries</p> <p>F. 110 kilograms</p> |
|---|---|--|

9. Authorized use:

|   |
|---|
| <p>A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.</p> <p>B. Any imaging and localization procedure permitted by 10 CFR 35.200.</p> <p>C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.</p> <p>D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.</p> <p>E. In vitro studies</p> <p>F. Shielding in brine accelerator.</p> |
|---|

Duplicate Duplicate  
CONDITIONS

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 3 PAGES

Duplicate MATERIALS LICENSE SUPPLEMENTARY SHEET Duplicate Duplicate

License Number 37-09938-01

Booklet or Reference Number 850-03119; SUB-9938

Amendment No. 48

10. Licensed material may be used only at the licensee's facilities at 21st and Lehigh Streets, Easton, Pennsylvania and at the Easton Imaging Center, 2690 Kingston Road, Easton, Pennsylvania.

11. The Radiation Safety Officer for this license is Walter Robinson, M.S.

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

| Authorized Users               | Material and Use                                |
|--------------------------------|---|
| Kenneth Krantz, M.D.           | 35.100; 35.200; 35.500; <u>In vitro</u> studies |
| Joel D. Neuman, M.D.           | 35.100; 35.200                                  |
| Barbara Dinsmore, M.D.         | 35.100; 35.200                                  |
| Stuart Jones, M.D.             | 35.100; 35.200; 35.300                          |
| Richard J. Toppie, M.D.        | 35.100; Depleted uranium for shielding          |
| Camilo E. Alcosoba, M.D.       | 35.100; Depleted uranium for shielding          |
| Jay Strauss, M.D.              | 35.100; 35.200; <u>In vitro</u> studies         |
| Nalini Mehta, M.D.             | 35.400; Depleted uranium for shielding          |
| Daniel A. N. Mascarenhas, M.D. | 35.200  |
| Thomas Little, M.D.            | 35.200  |
| Karoush Khalighi, M.D.         | 35.200  |
| Chandulal Patel, M.D.          | 35.200  |
| Nicholas M. Cardiges, M.D.     | 35.400  |
| Nimisha Deb, M.D.              | 35.400  |
| Dana Richard Burke, M.D.       | 35.100; 35.200                                  |
| Gregory Scott Foster, D.O.     | 35.100; 35.200                                  |
| Stephen Kaizak, M.D.           | 35.100; 35.200                                  |
| Marlene S. Backenstoss, M.D.   | 35.100; 35.200                                  |

Duplicate Duplicate Duplicate

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 3 PAGES

**MATERIALS LICENSE SUPPLEMENTARY SHEET** Duplicate Duplicate

License Number  
37-09938-01


Packet or Reference Number  
050-03119; SUB-9938

Amendment No. 48

assurance for decommissioning.

- 14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
- 15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated December 20, 1988
- B. Letter dated May 14, 1990
- C. Letter dated October 2, 1990
- D. Letter dated October 30, 1990
- E. Letter dated February 25, 1991
- F. Letter dated January 21, 1991
- G. Letter dated October 12, 1991
- H. Letter dated August 4, 1993
- I. Letter dated August 19, 1993
- J. Letter dated September 17, 1993
- K. Letter dated May 12, 2000
- L. Letter dated February 22, 2001
- M. Letter dated September 5, 2001



For the U.S. Nuclear Regulatory Commission

*Original signed by Michelle Beardley*

Date December 11, 2002

By

Michelle Beardley  
Nuclear Materials Safety Branch 1  
Division of Nuclear Materials Safety

Duplicate

Duplicate

Duplicate  
Region I  
King of Prussia, Pennsylvania 19386

**PUBLICATIONS**

Tomas KT, Poszgay JM, Avidan N, Ksiazek SJ, Overmoyer B, Blank KJ, and Prystowsky MB. Loss of Antigenic Epitopes as the Result of Env Gene Recombination in Retrovirus-Induced Leukemia in Immunocompetent Mice. Virology 1993; 192:587-595.

**PRIVATE PRACTICE**

**PREMIER HEART SPECIALISTS**  
241 North 13<sup>th</sup> Street  
Easton, PA 18042  
February, 1999 – Present

**HOSPITAL AFFILIATION**

**EASTON HOSPITAL**  
250 South 21<sup>st</sup> Street  
Easton, PA 18042  
February, 1999 – Present

**SACRED HEART HOSPITAL**  
421 Chew Street  
Allentown, PA 18102  
February, 1999- present

**LICENSURE**

Commonwealth of Pennsylvania  
License Number MD-051899-L

**CERTIFICATION**

National Board of Medical Examiners, 1992  
American Board of Internal Medicine, Diplomate, 1994

**PROFESSIONAL ORGANIZATIONS**

American College of Cardiology, Associate

**REFERENCES**

Available upon request

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

37-30468-01 PAGE 1 OF 3  
Amendment No. 02

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

|  |   |
|--|---|
| <p style="text-align: center;">Licensee</p> <p>1. Premier Heart Specialists</p> <p>2. 241 North 13th Street<br/>Easton, Pennsylvania 18042</p> | <p>In accordance with the letter dated January 18, 2001,</p> <p>3. License number 37-30468-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date August 31, 2008</p> <hr/> <p>5. Docket No. 030-34798<br/>Reference No.</p> |
|--|---|

|   |   |   |
|---|---|---|
| <p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material identified in 10 CFR 35.100</p> <p>B. Any byproduct material identified in 10 CFR 35.200</p>  | <p>7. Chemical and/or physical form</p> <p>A. Any radiopharmaceutical identified in 10 CFR 35.100</p> <p>B. Any radiopharmaceutical identified in 10 CFR 35.200 except generators and gas</p> | <p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p> |
| <p>9. Authorized use:</p> <p>A. Any uptake, dilution and excretion procedure approved in 10 CFR 36.100.</p> <p>B. Any imaging and localization procedure approved in 10 CFR 35.200.</p> |   |   |

**CONDITIONS**

- 10. Licensed material may be used only at the licensee's facilities located at 241 North 13th Street, Easton, Pennsylvania.
- 11. The Radiation Safety Officer for this license is Thomas Little, M.D.

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 of 3 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
37-30468-01Doctel or Reference Number  
030-34798

Amendment No. 02

12. Licensed material listed in Item 6 above is only authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

Authorized UsersMaterial and Use

Thomas Little, M.D.

35.100 and 35.200 for cardiovascular clinical procedures

Shahram Yazdani, M.D.

35.100 and 35.200 for cardiovascular clinical procedures

Stephen Ksiazek, M.D.

35.100 and 35.200 for cardiovascular clinical procedures

Jeffrey Cooper, M.D.

35.100 and 35.200

Brian McCandless, M.D.

35.100 and 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d), 40.36(b), and 70.25(d) for establishing financial assurance for decommissioning.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 of 3 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**


License Number  
**37-30468-01**

Docket or Reference Number  
**030-34798**

Amendment No. 02

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated July 20, 1998
- B. Letter dated August 24, 1998
- C. Letter dated January 18, 2001



For the U.S. Nuclear Regulatory Commission

Date March 28, 2001

By *Tereza Hall Darden*  
 Tereza Hall Darden  
 Nuclear Materials Safety Branch 1  
 Division of Nuclear Materials Safety  
 Region I  
 King of Prussia, Pennsylvania 19406

57176875



COMMONWEALTH OF PENNSYLVANIA  
DEPARTMENT OF ENVIRONMENTAL PROTECTION  
BUREAU OF RADIATION PROTECTION

Page 1 of 2 Pages  
License No. PA-0806  
Amendment No. 3

RADIOACTIVE MATERIALS LICENSE

Pursuant to the Radiation Protection Act, the Act of July 10, 1984 (No. 147, P.L. 688) and Title 25, Rules and Regulations, Article V, Radiological Health of the Pennsylvania Department of Environmental Protection, and in reliance on statements and representations heretofore made by the Licensee, a license is hereby issued authorizing the Licensee to receive, acquire, possess, transfer, and use radioactive material listed below for the purposes and at the places designated below. This license shall be deemed subject to all applicable rules, regulations, or orders of the Pennsylvania Department of Environmental Protection now or hereafter in effect and to any conditions specified below.

- 1. Licensee : In response to a renewal application  
Premier Heart Specialists : dated May 23, 2003
- 2. 241 North 13<sup>th</sup> Street : 3. License No. PA-0806 is amended as  
Easton, PA 18042 : follows:
- 4. Expiration Date: July 31, 2013

|  |                                     |  |
|--|-------------------------------------|--|
| 5. Radioactive material<br>(Element & mass number) | 6. Chemical and/or<br>physical form | 7. Maximum amount that licensee<br>may possess at any one time<br>under this license |
|--|-------------------------------------|--|

- |   |   |              |
|---|---|--------------|
| A. Any accelerator-produced<br>material applicable for use<br>identified in 10 CFR 35.100 | A. Any radiopharmaceutical<br>applicable for use<br>identified in 10 CFR 35.100 | A. As needed |
| B. Any accelerator-produced<br>material applicable for use<br>identified in 10 CFR 35.200 | B. Any radiopharmaceutical<br>applicable for use<br>identified in 10 CFR 35.200 | B. As needed |

- 8. Authorized Use
  - A. Any approved uptake, dilution and excretion procedures applicable to 10 CFR 35.100.
  - B. Any approved imaging and localization procedures applicable to 10 CFR 35.200.

CONDITIONS

- 9. Licensed material may be used only at the licensee's facilities located at 241 North 13<sup>th</sup> Street, Easton, PA 18042.
- 10. Radiation Safety Officer: Thomas Little, M.D.
- 11. Licensed material listed in Item 5 above is authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:

| <u>Authorized Users</u> | <u>Material and Use (10 CFR)</u> |
|-------------------------|----------------------------------|
| Jeffrey Cooper          | 35.100; 35.200                   |
| Brian McCandless, M.D.  | 35.100; 35.200                   |
| Thomas Little, M.D.     | 35.100 (New Part 35)             |
| Stephen Ksiazek, M.D.   | 35.100 (New Part 35)             |



COMMONWEALTH OF PENNSYLVANIA  
DEPARTMENT OF ENVIRONMENTAL PROTECTION  
BUREAU OF RADIATION PROTECTION

Page 2 of 2 Pages  
License No. PA-0806  
Amendment No. 3

**RADIOACTIVE MATERIALS LICENSE**

- 12. The licensee shall conduct a physical inventory every 6 months to account for all sealed sources and devices containing licensed material received and possessed pursuant to 10 CFR 35.67, 35.400 and 35.500 incorporated by reference.
- 13. The licensee may transport licensed material, or deliver licensed material to a carrier for transport, in accordance with 25 Pa. Code Chapter 230, "Packaging and Transportation of Radioactive Material" and the provisions of 10 CFR Part 71 incorporated by reference.
- 14. In addition to the possession limits in Item 7, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified and incorporated by reference in 10 CFR 30.35(d), 40.36(b) and 70.25(d) for establishing financial assurance for decommissioning relative to isotopes with half life greater than 120 days.
- 15. Notwithstanding the requirements set forth in this license, the licensee shall comply with the regulations set forth in Title 25 of the Pennsylvania Code Article V "Radiological Health" and the U.S. Nuclear Regulatory Commission, Title 10 Code Of Federal Regulations Parts 19-150 incorporated by reference.
- 16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The Department of Environmental Protection's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated July 20, 1998
- B. Letter dated January 28, 2001
- C. Renewal application dated May 23, 2003

For the Pennsylvania Department  
of Environmental Protection

Ronald J. Hamm  
Bureau of Radiation Protection  
P. O. Box 8469  
Harrisburg, PA 17105-8469

Date: June 13, 2003

This is to acknowledge the receipt of your letter/application dated

4/27/2007, and to inform you that the initial processing which includes an administrative review has been performed.

AMEND. 29-01101-03 There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

---

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned Mail Control Number 140466.  
When calling to inquire about this action, please refer to this control number.  
You may call us on (610) 337-5398, or 337-5260.